Although further studies will be necessary, our results suggest that targeting BRAFV600E and CDK4/6 in aggressive thyroid cancer can trigger apoptosis by overcoming CDK4/6-dependent cell cycle checkpoints dysfunctions which could allow or even lead to genomic instability. Here, CDK4 is linked to thyroid gland carcinoma.